Acrivon reports promising preclinical cancer drug data

WATERTOWN, Mass. - Acrivon Therapeutics, Inc. (NASDAQ:ACRV), a clinical-stage biopharmaceutical company, announced preclinical study results for two of its cancer drug candidates at the American Association for Cancer Research (AACR) Annual Meeting. The company presented data supporting the anticancer activity of ACR-2316 and the identification of a potential treatment combination to overcome resistance to ACR-368, its clinical-stage CHK1/2 inhibitor.

ACR-2316, a dual inhibitor of WEE1 and PKMYT1, showed potent anticancer effects in preclinical models. Compared to benchmark inhibitors adavosertib and lunresertib, ACR-2316 demonstrated greater potency across a range of human tumor cell lines and patient-derived xenograft models, particularly in ovarian cancer. The company plans to advance ACR-2316 into clinical development as a monotherapy.

In addition, Acrivon's proprietary proteomics platform, AP3, identified ultra-low dose gemcitabine (ULDG) as a sensitizer for resistant ovarian cancer cells to ACR-368. Preclinical studies confirmed that ULDG can enhance the efficacy of ACR-368, with subsequent upregulation of biomarkers that may predict responsive tumors.

Acrivon's AP3 platform is designed to optimize drug development by identifying patient-specific tumor sensitivities and resistance mechanisms, supporting the creation of targeted therapies and companion diagnostics.

The company is advancing its lead candidate, ACR-368, in a Phase 2 trial for patients with platinum-resistant ovarian or endometrial cancer, based on predicted sensitivity by the OncoSignature assay. While the assay has not yet received regulatory approval, it has been granted Breakthrough Device designation by the FDA for identifying potential responders to ACR-368 treatment.

Acrivon's approach to drug development, enabled by AP3, aims at matching precision oncology medicines to patients most likely to benefit from them. These recent findings underscore the company's commitment to this strategy and its potential to bring new treatments to market.

This article is based on a press release statement and contains no endorsements of claims. Acrivon has made forward-looking statements regarding its drug candidates and development strategies, which are subject to risks and uncertainties as detailed in their SEC filings.

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been showcasing its innovative approach to cancer treatment, which could be of significant interest to investors monitoring the biopharmaceutical sector. Recent data from InvestingPro provides a snapshot of the company's financial health and market performance.

The company's market capitalization stands at 217.77 million USD, reflecting its position in the market. Despite the company's promising research developments, the current P/E ratio is -2.61, indicating that investors may be cautious due to the company's lack of profitability over the last twelve months. This is further underscored by a negative EBITDA growth rate of -106.13% for the same period.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

On the performance front, Acrivon's stock has experienced a strong return over the last month and three months, with price total returns of 19.39% and 27.65%, respectively. This could signal growing investor confidence in the company's drug development prospects, despite the fact that analysts have revised their earnings downwards for the upcoming period, as per InvestingPro Tips.

Two key InvestingPro Tips for Acrivon are that the company holds more cash than debt on its balance sheet, which is a positive sign of financial stability, and that its liquid assets exceed short term obligations, suggesting good short-term financial health. However, the company is quickly burning through cash and analysts do not anticipate it will be profitable this year. These factors may influence investment decisions, especially for those looking at long-term growth potential.

For more detailed analysis and additional InvestingPro Tips, investors can visit InvestingPro's ACRV page. Currently, there are 11 more tips available on InvestingPro that could provide deeper insights into Acrivon’s financials and market performance. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.